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with a 10-year follow-up, an adjuvant therapy with Herceptin®
would avoid 49.7 loco-regional recurrences, 179.5 distant recur-
rences and 133.4 deaths. Incremental cost-utility ratio of Her-
ceptin® was €18,282/QALY gained at lifetime horizon, which is
well below the commonly accepted threshold of €45,000/QALY
gained. CONCLUSIONS: Utilization of Herceptin® as an adju-
vant therapy in patients with primary HER-2 positive breast
cancer improves patient survival with an acceptable cost-utility
ratio in the French setting.
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OBJECTIVES: To estimate the cost-effectiveness of rituximab
plus cyclophosphamide, vincristine, and prednisone (RCVP)
compared to CVP alone in previously untreated NHL patients
with advanced follicular lymphoma from a Canadian perspec-
tive. METHODS: A cost-utility analysis was performed from a
Ministry of Health perspective over a 10-year time horizon using
a Markov health state transition model. All patients (mean age
53 years) enter the model in a progression-free health state. Sur-
vival was estimated from Kaplan-Meier curves from a published
phase III trial of RCVP versus CVP in patients with stage III or
IV follicular lymphoma (median follow-up 31 months) and data
from the Scotland and Newcastle Lymphoma Group (SNLG)
registry using a line of best ﬁt approach. Utilities for quality of
life were assessed using the EQ-5D in a population of NHL
patients from the UK. Direct annual medical costs including drug
acquisition, administration and preparation were estimated from
published sources. All costs are reported in 2005 CAD. Costs
and outcomes were discounted at a rate of 5%. In order to
address uncertainty in point estimates, one way sensitivity analy-
ses were also performed. RESULTS: The addition of rituximab
to CVP resulted in an additional 1.3 years of progression free
survival and 0.58 quality adjusted life years (QALYs) over CVP
alone. The cost of RCVP therapy was $43,445 compared to
$22,891 for CVP. The incremental cost-utility ratio was
$35,753/QALY. Results from one-way sensitivity analyses
ranged from a low of $22,079/QALY to a high of $55,338/
QALY. CONCLUSION: The addition of rituximab to a regimen
of CVP represents a cost-effective treatment alternative in previ-
ously untreated NHL patients according to conventionally
accepted ratios.
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OBJECTIVES: The TAC adjuvant chemotherapy regimen 
compared to FAC improves the disease free survival (DFS) and
overall survival (OS) rates signiﬁcantly in women with operable
node positive breast cancer, but the cost-effectiveness of this
better efﬁcacy was not evaluated. METHODS: We developed 
a model describing the clinical history of women with node 
positive breast cancer that projected improvements in lifetime
quality adjusted life years (QALY), long-term costs, and cost-
effectiveness of the adjuvant treatment TAC compared to FAC.
The base case was a 50 years old woman with unilateral node
positive breast cancer submitted to mastectomy and without
metastasis. Transition probabilities came from the BCIRG 001
study and other major studies; the quality of life for each health
state was based on the medical literature. The local management
and costs of each health state was based on a Delphi panel
according to the private health care perspective. Outcomes were
discounted at 3% annually. Sensitivity analyses and a second
order Monte Carlo simulation were performed. RESULTS: The
lifetime horizon analysis showed: DFS of 32.5% and 29% and
OS of 38% and 33%, for TAC and FAC, respectively; TAC
increased life expectancy (LY) in 1.20 years and in quality
adjusted life years (QALY) there was a 1.08 year gain, in com-
parison to FAC; the incremental cost per QALY was R$9476.92;
the FAC group expense in the metastasis state, in ﬁfteen years,
was bigger than the whole cost for the treatment of recurrence
states, for a whole life, with TAC; the Monte Carlo simulation
showed that TAC is cost-effective 98% of the times and is cost-
saving 18% of the times. CONCLUSION: Improvements in DFS
and OS with adjuvant TAC regimen in women with operable
node positive breast cancer improves patient outcomes in terms
of LY and QALY with an acceptable cost-effectiveness ratio in
Brazil.
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OBJECTIVES: Fulvestrant (Faslodex) is a well-tolerated estro-
gen receptor antagonist that is at least as effective as anastrozole
in patients who have progressed or recurred on tamoxifen. A
health economic model was developed to estimate the incre-
mental cost per quality adjusted life year (QALY) gained when
fulvestrant is included as an additional endocrine therapy step
for postmenopausal women with hormone receptor positive
(HR+) advanced breast cancer (ABC). METHODS: A seven-state
Markov model was developed from a UK NHS perspective. This
followed patients over their treatment for ABC, simulated over
a 10-year time horizon. The model compared the costs and ben-
eﬁts of two cohorts of patients—one with and one without the
addition of fulvestrant to the endocrine treatment sequence.
Clinical data were collated from published trials. Resource uti-
lization data were obtained from published literature and a
survey of ﬁve UK physicians. Unit costs were taken from pub-
lished sources. Each Markov cycle lasted 28 days. Major
assumptions were validated via a survey of seven UK physicians.
Costs and beneﬁts were discounted at 3.5%. The robustness 
of results was tested using a probabilistic sensitivity analysis.
RESULTS: In a cohort of 1000 postmenopausal women with
HR+ ABC, the model suggested that a treatment sequence with
fulvestrant as a third endocrine therapy step leads to a gain 
of 41 QALYs at an additional cost of ≤69,910, as compared 
to a sequence without fulvestrant. The estimated incremental
cost-effectiveness ratio (ICER) of including fulvestrant in the
endocrine treatment sequence was ≤1705 per QALY. Cost-
effectiveness acceptability curves indicated over a 70% pro-
bability that the cost per QALY gained would be lower 
than ≤20,000, a commonly accepted UK threshold for cost-
effectiveness. CONCLUSIONS: Based on this economic model,
the use of fulvestrant as an additional endocrine therapy step in
the treatment of HR+ ABC is a cost-effective treatment strategy.
